The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.
Globally our industry is researching and developing more than 7,000 new medicines.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.
1. The review of immunisation cost-effectiveness methodology began following the appraisal by the Joint Committee on Vaccinations and Immunisation (JCVI) of the vaccine for Meningococcal B. During this review, concerns were raised by the JCVI, health professionals, patient groups, industry and many members of the public, that the system used to assess cost-effectiveness may not be appropriate particularly when considering vaccination against severe diseases which disproportionately affected the youngest members of the population. In October 2013 JCVI suggested that a Working Group on Cost-effectiveness be established to examine the question of how the impact of vaccination programmes to prevent rare diseases of high severity could best be assessed and whether there were aspects of cost-effectiveness in relation specifically to children that should be considered.
2. The petition on access to the Meningococcal B vaccine was the third largest petition ever submitted to the House of Commons petitions committee.